The expression of the Sprouty 1 protein inversely correlates with growth, proliferation, migration and invasion of ovarian cancer cells

Journal of Ovarian Research

David Lawson Morris¹  Ai-Qun Wei²  Anahid Ehteda¹  Afshin Amini¹  Samar Masoumi-Moghaddam¹ 

[1]Department of Surgery, St George Hospital, The University of New South Wales, Gray Street, Kogarah, Sydney NSW 2217, Australia

[2]Department of Orthopedic Surgery, St. George Hospital, The University of New South Wales, Gray Street, Kogarah, Sydney NSW 2217, Australia

关键词: Survival;    Proliferation;    Migration;    Invasion;    Ovarian cancer;    Spry1;   

Others  :  801126
DOI  :  10.1186/1757-2215-7-61

 received in 2014-05-01, accepted in 2014-06-02,  发布年份 2014

【 摘 要 】

Background

Our recent study on a panel of human ovarian cancer cells revealed that SKOV-3 cells barely express the Sprouty isoform 1 (Spry1) while 1A9 cells maintain it at a level similar to normal ovarian cells. Here we investigated the functional outcomes of induced alterations in the expression of Spry1 in the two cell lines in vitro.

Methods

Using the Spry1 specific plasmid and siRNA, the expression of Spry1 was induced and conversely silenced in SKOV-3 and 1A9 cells, respectively. The functional outcome was investigated by means of proliferation, MTT, scratch-wound, migration and invasion assays and selection of the stable clones. Mechanism of the effect was explored by Western blot.

Results

In the Spry1-transfected SKOV-3 cells, a significant reduction in growth and proliferation was evident. Stable clones of the Spry1-transfected SKOV-3 were almost undetectable after day 14. The number of migrated and invaded cells and the percentage of the scratch closure were significantly lower in the Spry1-transfected group. Spry1 silencing in 1A9 cells, on the other hand, led to a significant increase in cell growth and proliferation. The number of migrated and invaded cells and the percentage of the scratch closure significantly increased in Spry1-silenced 1A9 group. Mechanistically, overexpression of Bax, activation of caspases 3, 7, 8 and 9, cleavage of PARP and attenuation of Bcl-2 and Bcl-xl were observed along with reduced activation of Erk and Akt and increased amount and activity of PTEN in the Spry1-transfected SKOV-3 cells.

Conclusions

Here, we report the inverse correlation between the expression of Spry1 and growth, proliferation, invasion and migration of ovarian cancer cells.

【 授权许可】

   
2014 Masoumi-Moghaddam et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Hacohen N, Kramer S, Sutherland D, Hiromi Y, Krasnow MA: Sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways. Cell 1998, 92:253-263.
• [2]Masoumi-Moghaddam S, Amini A, Morris DL: The developing story of Sprouty and cancer. Cancer Metastasis Rev 2014, 33:1-26.
• [3]Lo TL, Yusoff P, Fong CW, Guo K, McCaw BJ, Phillips WA, Yang H, Wong ES, Leong HF, Zeng Q, Putti TC, Guy GR: The ras/mitogen-activated protein kinase pathway inhibitor and likely tumor suppressor proteins, sprouty 1 and sprouty 2 are deregulated in breast cancer. Cancer Res 2004, 64:6127-6136.
• [4]Kwabi-Addo B, Wang J, Erdem H, Vaid A, Castro P, Ayala G, Ittmann M: The expression of Sprouty1, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer. Cancer Res 2004, 64:4728-4735.
• [5]Jin XL, Sun QS, Liu F, Yang HW, Liu M, Liu HX, Xu W, Jiang YY: microRNA 21-mediated suppression of Sprouty1 by Pokemon affects liver cancer cell growth and proliferation. J Cell Biochem 2013, 114:1625-1633.
• [6]Macia A, Gallel P, Vaquero M, Gou-Fabregas M, Santacana M, Maliszewska A, Robledo M, Gardiner JR, Basson MA, Matias-Guiu X, Encinas M: Sprouty1 is a candidate tumor-suppressor gene in medullary thyroid carcinoma. Oncogene 2012, 31:3961-3972.
• [7]Takahashi M, Rhodes DR, Furge KA, Kanayama H, Kagawa S, Haab BB, Teh BT: Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci U S A 2001, 98:9754-9759.
• [8]Masoumi Moghaddam S, Amini A, Wei AQ, Pourgholami MH, Morris DL: Initial report on differential expression of sprouty proteins 1 and 2 in human epithelial ovarian cancer cell lines. J Oncol 2012, 373826:1-9.
• [9]Bani MR, Nicoletti MI, Alkharouf NW, Ghilardi C, Petersen D, Erba E, Sausville EA, Liu ET, Giavazzi R: Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts. Mol Cancer Ther 2004, 3:111-121.
• [10]Bijman MN, van Berkel MP, van Nieuw Amerongen GP, Boven E: Interference with actin dynamics is superior to disturbance of microtubule function in the inhibition of human ovarian cancer cell motility. Biochem Pharmacol 2008, 76:707-716.
• [11]Zhang SL, Lu YM, Meng LR, Zhao YY: Inhibition of invasive and chemotactic abilities of SKOV3 cells by human epithelial growth receptor-2 small interfering RNA. Zhonghua Fu Chan Ke Za Zhi 2007, 42:48-53.
• [12]Lu C, Shahzad MM, Wang H, Landen CN, Kim SW, Allen J, Nick AM, Jennings N, Kinch MS, Bar-Eli M, Sood AK: EphA2 overexpression promotes ovarian cancer growth. Cancer Biol Ther 2008, 7:1098-1103.
• [13]Xu TM, Cui MH, Xin Y, Gu LP, Jiang X, Su MM, Wang DD, Wang WJ: Inhibitory effect of ginsenoside Rg3 on ovarian cancer metastasis. Chin Med J (Engl) 2008, 121:1394-1397.
• [14]Swaminathan V, Mythreye K, O'Brien ET, Berchuck A, Blobe GC, Superfine R: Mechanical stiffness grades metastatic potential in patient tumor cells and in cancer cell lines. Cancer Res 2011, 71:5075-5080.
• [15]Gross I, Bassit B, Benezra M, Licht JD: Mammalian sprouty proteins inhibit cell growth and differentiation by preventing ras activation. J Biol Chem 2001, 276:46460-46468.
• [16]Impagnatiello MA, Weitzer S, Gannon G, Compagni A, Cotten M, Christofori G: Mammalian sprouty-1 and −2 are membrane-anchored phosphoprotein inhibitors of growth factor signaling in endothelial cells. J Cell Biol 2001, 152:1087-1098.
• [17]Lee S, Bui Nguyen TM, Kovalenko D, Adhikari N, Grindle S, Polster SP, Friesel R, Ramakrishnan S, Hall JL: Sprouty1 inhibits angiogenesis in association with up-regulation of p21 and p27. Mol Cell Biochem 2010, 338:255-261.
• [18]Huebert RC, Li Q, Adhikari N, Charles NJ, Han X, Ezzat MK, Grindle S, Park S, Ormaza S, Fermin D, Miller LW, Hall JL: Identification and regulation of Sprouty1, a negative inhibitor of the ERK cascade, in the human heart. Physiol Genomics 2004, 18:284-289.
• [19]Sabatel C, Cornet AM, Tabruyn SP, Malvaux L, Castermans K, Martial JA, Struman I: Sprouty1, a new target of the angiostatic agent 16 K prolactin, negatively regulates angiogenesis. Mol Cancer 2010, 9:231. BioMed Central Full Text
• [20]Xiang Q, Lin G, Xu J, Zheng S, Chen S, Zhou K, Wang T: The role of caveolin1 and sprouty1 in genistein's regulation of vascular smooth muscle cell and endothelial cell proliferation. Eur J Pharmacol 2010, 648:153-161.
• [21]Mekkawy AH, De Bock CE, Lin Z, Morris DL, Wang Y, Pourgholami MH: Novel protein interactors of urokinase-type plasminogen activator receptor. Biochem Biophys Res Commun 2010, 399:738-743.
• [22]Mekkawy AH, Morris DL: Human Sprouty1 suppresses urokinase receptor-stimulated cell migration and invasion. ISRN Biochemistry 2013, 2013:7.
• [23]Lee CC, Putnam AJ, Miranti CK, Gustafson M, Wang LM, Vande Woude GF, Gao CF: Overexpression of sprouty 2 inhibits HGF/SF-mediated cell growth, invasion, migration, and cytokinesis. Oncogene 2004, 23:5193-5202.
• [24]Edwin F, Singh R, Endersby R, Baker SJ, Patel TB: The tumor suppressor PTEN is necessary for human Sprouty 2-mediated inhibition of cell proliferation. J Biol Chem 2006, 281:4816-4822.
• [25]Fong CW, Chua MS, McKie AB, Ling SH, Mason V, Li R, Yusoff P, Lo TL, Leung HY, So SK, Guy GR: Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma. Cancer Res 2006, 66:2048-2058.
• [26]Wang C, Delogu S, Ho C, Lee SA, Gui B, Jiang L, Ladu S, Cigliano A, Dombrowski F, Evert M, Calvisi DF, Chen X: Inactivation of Spry2 accelerates AKT-driven hepatocarcinogenesis via activation of MAPK and PKM2 pathways. J Hepatol 2012, 57:577-583.
• [27]Vanas V, Muhlbacher E, Kral R, Sutterluty-Fall H: Sprouty4 interferes with cell proliferation and migration of breast cancer-derived cell lines. Tumour biol 2014, 35(5):4447-4456.
• [28]Polytarchou C, Iliopoulos D, Hatziapostolou M, Kottakis F, Maroulakou I, Struhl K, Tsichlis PN: Akt2 regulates all Akt isoforms and promotes resistance to hypoxia through induction of miR-21 upon oxygen deprivation. Cancer Res 2011, 71:4720-4731.